CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 1 filers reported holding CLOVIS ONCOLOGY INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $915,000 | -61.6% | 156,969 | -55.5% | 0.21% | -57.7% |
| Q2 2020 | $2,383,000 | -0.4% | 353,085 | -6.1% | 0.49% | -3.5% |
| Q1 2020 | $2,392,000 | -43.8% | 376,085 | -8.0% | 0.51% | -25.2% |
| Q4 2019 | $4,260,000 | +151.2% | 408,625 | -5.3% | 0.68% | +137.6% |
| Q3 2019 | $1,696,000 | -73.6% | 431,425 | 0.0% | 0.29% | -72.2% |
| Q2 2019 | $6,415,000 | -31.9% | 431,425 | +13.6% | 1.03% | -31.8% |
| Q1 2019 | $9,426,000 | +56.4% | 379,777 | +13.2% | 1.51% | +49.3% |
| Q4 2018 | $6,027,000 | +10.6% | 335,577 | +80.8% | 1.01% | +18.6% |
| Q3 2018 | $5,450,000 | -31.1% | 185,577 | +6.7% | 0.85% | -35.0% |
| Q2 2018 | $7,907,000 | +20.9% | 173,892 | +40.4% | 1.31% | +11.5% |
| Q1 2018 | $6,541,000 | -36.3% | 123,892 | -17.9% | 1.18% | -31.7% |
| Q4 2017 | $10,267,000 | -15.9% | 150,992 | +2.0% | 1.73% | -7.2% |
| Q3 2017 | $12,203,000 | – | 148,092 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |